THE ISOPROSTANES: THEIR QUANTIFICATION AS AN INDEX OF OXIDANT STRESS STATUS IN VIVO^†

REFERENCES

• Halliwell B., Grootveld M. The measurement of free radical reactions in humans. FEBS Lett. 1987; 213: 9–14
   PubMed Web of Science ®Google Scholar
• Morrow J. D., Hill K. E., Burk R. F., Nammour T. M., Badr K. F., Roberts L. J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA 1990; 87: 9383–9397
   PubMed Web of Science ®Google Scholar
• Morrow J. D., Roberts L. J. Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol. 1999; 300: 3–12
   PubMed Web of Science ®Google Scholar
• Morrow J. D., Harris T. M., Roberts L. J. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: Analytical ramifications for measurement of eicosanoids. Anal. Biochem. 1990; 184: 1–10
   PubMed Web of Science ®Google Scholar
• Taber D. F., Morrow J. D., Roberts L. J. A nomenclature system for the isoprostanes. Prostaglandins 1997; 53: 63–67
   PubMed Web of Science ®Google Scholar
• Morrow J. D., Awad J. A., Boss H. J., Blair I. A., Roberts L. J. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. USA 1992; 89: 10,721–10,725
   Google Scholar
• Morrow J. D., Chen Y., Brame C. J., Yang J., Sanchez S. C., Xu J., Zackert W. E., Awad J. A., Roberts L. J. The isoprostanes: Unique prostaglandin-like products of free radical-initiated lipid peroxidation. Drug Metab. Rev. 1999; 31: 117–139
   PubMed Web of Science ®Google Scholar
• Pratico D., Reilly M., Lawson J., Delanty N., FitzGerald G. A. Formation of 8-iso-prostaglandin F2αby human platelets. Agents Actions 1995; 45(Suppl.)27–31
   PubMedGoogle Scholar
• Feillet-Coudray C., Tourtauchaux R., Niculescu N., Rock E., Tauveron I., Alexandre-Gouabau M., Rayssiguier Y., Jalenques I., Mazur A. Plasma levels of 8-epi-PGF2α, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radical Biol. Med. 1999; 27: 463–469
   PubMed Web of Science ®Google Scholar
• Morrow J. D., Roberts L. J. The isoprostanes: Unique bioactive products of lipid peroxidation. Prog. Lipid Res. 1997; 36: 1–21
   PubMed Web of Science ®Google Scholar
• Morrow J. D., Awad J. A., Kato T., Takahashi K., Badr K. F., Roberts L. J., Burk R. F. Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. J. Clin. Invest. 1992; 90: 2502–2507
   PubMed Web of Science ®Google Scholar
• Awad J. A., Morrow J. D., Hill K. E., Roberts L. J., Burk R. F. Detection and localization of lipid peroxidation in selenium-and vitamin-E deficient rats using F2-isoprostanes. J. Nutr. 1994; 124: 810–816
   PubMed Web of Science ®Google Scholar
• Burk R. F., Hill K. E., Awad J. A., Morrow J. D., Kato T., Cockell K. A., Lyons P. R. Pathogenesis of diquat-induced liver necrosis in selenium-deficientjyrats: Assessment of the roles of lipid peroxidation and selenoprotein P. Hepatology 1995; 21: 561–569
   PubMed Web of Science ®Google Scholar
• Awad J. A., Roberts L. J., Burk R. F., Morrow J. D. Isoprostanes-prostaglandin-like compounds formed in vivo independently of cyclooxygenase. Gastroenterol. Clin. North Am. 1996; 25: 409–427
   PubMed Web of Science ®Google Scholar
• Schelling J. R., Linas S. L. Hepatorenal syndrome. Semin. Nephrol. 1990; 10: 565–570
   PubMed Web of Science ®Google Scholar
• Morrow J. D., Moore K. P., Awad J. A., Ravenscraft M. D., Marini G., Badr K. F., Williams R., Roberts L. J. Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome. J. Lipid Med. 1993; 6: 417–420
   PubMedGoogle Scholar
• Mason R. P., Fischer V. Free radicals of acetaminophen: Their subsequent reactions and toxicological significance. Fed. Proc. 1986; 45: 2493–2499
   PubMedGoogle Scholar
• Murrell D. F. A radical proposal for the pathogenesis of scleroderma. J. Am. Acad. Dermatol. 1993; 28: 78–85
   PubMed Web of Science ®Google Scholar
• Stein C. M., Tanner S. B., Awad J. A., Roberts L. J., Morrow J. D. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum. 1996; 39: 1146–1150
   PubMed Web of Science ®Google Scholar
• Church D. F., Pryor W. A. Free-radical chemistry of cigarette smoke and its toxicological complications. Environ. Health Perspect. 1985; 64: 111–126
   PubMed Web of Science ®Google Scholar
• Morrow J. D., Frei B., Longmire A. W., Gaziano J. M., Lynch S. M., Shyr Y., Strauss W. E., Oates J. A., Roberts L. J. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: Smoking as a cause of oxidative damage. N. Engl. J. Med. 1995; 332: 1198–1203
   PubMed Web of Science ®Google Scholar
• Reilly M., Delanty N., Lawson J. A., FitzGerald G. A. Modulation od oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94: 19–25
   PubMed Web of Science ®Google Scholar
• Roberts L. J., Morrow J. D. Isoprostanes as markers of lipid peroxidation in atherosclerosis. Molecular and Cellular Basis of Inflammation, C. N. Serhan, P. A. Ward. Humana Press, Totowa, NJ 1999; 141–163
   Google Scholar
• Markesbery W. R. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biol. Med. 1997; 23: 137–147
   Google Scholar
• Montine T. J., Markesbery W. R., Morrow J. D., Roberts L. J. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann. Neurol. 1998; 44: 410–413
   PubMed Web of Science ®Google Scholar
• Montine T. J., Markesbery W. R., Zackert w., Sanchez S. C., Roberts L. J., Morrow J. D. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with ApoE genotype in Alzheimer's disease patients. Am. J. Pathol. 1999; 155: 863–868
   PubMed Web of Science ®Google Scholar
• Montine T. J., Beal M. F., Cudkowicz M. E., O'Donnell H., Margolin R. A., McFarland L., Bachrach A. F., Zackert W. E., Roberts L. J., Morrow J. D. Increased CSF F2-isoprostanes in probable AD. Ann. Neurol. 1999; 52: 562–565
   Google Scholar